Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Simple method turns human skin cells into immune-fighting white blood cells

September 9, 2014 – 5:00 pm | Edit Post

LA JOLLA—For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.

Simple method turns human skin cells into immune-fighting white blood cells

September 9, 2014 – 5:00 pm | Edit Post

LA JOLLA—For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.

ViaCyte starts diabetes trial

September 9, 2014 – 3:16 pm | Edit Post

ViaCyte starts human testing of a first-ever diabetes treatment derived from stem cells.

ViaCyte starts diabetes trial

September 9, 2014 – 3:16 pm | Edit Post

ViaCyte starts human testing of a first-ever diabetes treatment derived from stem cells.

SGB Reports Success With Crop; Co. Closes $11M Series C Financing Round

September 9, 2014 – 3:13 pm | Edit Post

SGB Inc., a San Diego-based agricultural biotechnology and seed company, closed an $11 million Series C financing round.

Clinical Trial To Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

September 9, 2014 – 3:00 pm | Edit Post

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a …

Clinical Trial To Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

September 9, 2014 – 3:00 pm | Edit Post

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a …

Jatropha grower SGB raises $11 million

September 9, 2014 – 2:40 pm | Edit Post

Saying its high-yield jatropha is ready to sell, biotech SGB has raised $11 million.

Jatropha grower SGB raises $11 million

September 9, 2014 – 2:40 pm | Edit Post

Saying its high-yield jatropha is ready to sell, biotech SGB has raised $11 million.

After Restructuring, SGB Raises $11M for Jatropha Commercialization

September 9, 2014 – 2:31 pm | Edit Post
After Restructuring, SGB Raises $11M for Jatropha Commercialization

San Diego-based SGB, the agricultural biotech previously known as SG Biofuels, says today it has raised $11 million in a Series C round of financing that will be used to drive its revised…

[[Click headline to continue reading.]]